Go deep into
modeling & simulation.
Research notes, regulatory analysis, and platform updates from the team building the simulation layer for drug development.
BLOG SECTIONSynthetic Data for Rare Subgroups – A Decision-Grade Tool to Inform Drug Development
In drug development, access to diverse and representative patient data is often a limiting factor, especially when studying rare subgroups. This is where synthetic data can offer p…
BLOG SECTIONSynthetic Data – Are We All Talking About the Same Thing?
Synthetic Data' – Are We All Talking About the Same Thing? In the rapidly evolving world of healthcare and drug development, data is the driving force behind innovation. Yet, the l…
BLOG SECTIONFDA's Strategic Roadmap to Phase Out Animal Testing: How Computational Models Are Revolutionizing Drug Development
The Paradigm Shift in Preclinical Testing The FDA has announced a strategic shift away from animal testing, citing that over 90% of drugs successful in animals fail FDA approval du…
BLOG SECTIONInSilicoTrials Highlighted in HSBC Venture Healthcare Report for 1H 2024
The HSBC Healthcare Annual Report for the first half of 2024 provides an extensive analysis of the healthcare sector, focusing on trends in venture capital investments, biopharma,…
BLOG SECTIONFDA DRAFT GUIDANCE: Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies Guidance for Industry
In recent years, the US Congress and the US Food and Drug Administration (FDA) have emphasized the importance of including underrepresented populations in clinical trials. This pus…
BLOG SECTIONCharting New Horizons for Clinical Trials: InSilicoTrials at DIA 2024
InSilicoTrials recently participated in the DIA 2024 Global Annual Meeting, ( 16-20 June, San Diego), sharing valuable insights on the use of in silico trials, digital twins, and A…
BLOG SECTIONIn Silico Technologies: A Strategic Imperative for Accelerating Breakthroughs and Market Leadership for FDA-Regulated Products
InSilicoTrials recently collaborated with a team of experts led by Tina M. Morrison on a significant initiative supported by the FDA and the U.S. Department of Health and Human Ser…
BLOG SECTIONLiving with Amyotrophic Lateral Sclerosis
The BRAINTEASER Community of Practice Second webinar Advances in digital technology are helping us to predict the onset of a disease, how it will progress, or which is the best tre…
BLOG SECTIONAxoltis Pharma receives authorization to launch SEALS - phase II clinical trial for ALS patients with drug candidate NX210c
InSilicoTrials partners with Axoltis Pharma to leverage advanced modeling technology, generating predictive analyses of disease progression in virtual subjects based on the baselin…
BLOG SECTIONTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
InSilicoTrials collaborates with Telomir Pharmaceuticals, applying cutting-edge AI and simulation technologies to optimize the development of Telomir-1, a promising agent in the ba…
BLOG SECTIONRevolutionizing Healthcare: The Emergence and Impact of Synthetic Data in Life Sciences
The realm of healthcare and life sciences is undergoing a transformative shift, fueled by the advent and integration of data-driven technologies. At the forefront of this revolutio…
BLOG SECTIONWomen in Multiple Sclerosis webinar: take-home messages
In the Webinar: Women in Multiple Sclerosis, hosted by the Community of Practice of the BRAINTEASER project, we focused on the role of hormones on the onset and progression of the…
BLOG SECTIONThe book ?????? ???? ?????????? ???????? Published Open Access on Springer Nature
InSilicoTrials is thrilled to announce the publication of " ?????? ??? d ?????????? ???????? - Best practices for the use of computational modelling & simulation in the regulatory…
BLOG SECTIONHarnessing AI, Big Data, and the European Health Data Space for Revolutionary Advances in Research and Clinical Practice
At the Brain Innovation Days held in Brussels on October 26-27, 2023, organised by the European Brain Council, representatives from the BRAINTEASER project and from other pertinent…
BLOG SECTIONThe iDPP@CLEF Challenge as a Way to Open Science
iDPP@CLEF [1] is an open evaluation challenge to assess the performance of Artificial Intelligence (AI) algorithms to predict the progression of Amyotrophic Lateral Sclerosis (ALS)…
BLOG SECTIONAxoltis Pharma's Breakthrough in Neurodegenerative Disease Research, Supported by InSilicoTrials
Axoltis Pharma is at the forefront of developing treatments for neurodegenerative diseases, with their phase 1b clinical trial of NX210c marking a notable achievement in the field.…
BLOG SECTIONAI state-of-play around clinical research – BRAINTEASER Community of Practice
The life sciences sector is beginning to experience the transformative effects of AI, with numerous applications offering clinical, operational, and medical advantages. Unlike othe…
BLOG SECTIONCutting-edge Big Data initiative seeks to provide crucial support to people affected by Amyotrophic Lateral Sclerosis and Multiple Sclerosis
Mamede de Carvalho, a renowned neurologist and the head of the Amyotrophic Lateral Sclerosis (ALS) Clinic at Centro Hospitalar Universitário Lisboa Norte (CHULN), situated at the p…
IN SILICO TALKSInSilicoTrials’ Talks Series Listen our IST Customer Testimonial - Yann Godfrin, CEO of Axoltis Pharma
Welcome back to InSilicoTrials’ Talks! We're excited to launch our IST Customer Testimonials’ initiative, a series dedicated to hearing directly from our clients. Today, we feature…
BLOG SECTIONCollaboration Between InSilicoTrials and Biofarma Group Explores the Benefits of In Silico Technology in Clinical Research
InSilicoTrials has collaborated effectively with Biofarma Group to harness the potential of in silico technology for clinical research. In this collaboration, InSilicoTrials utiliz…
Cutting-edge Big Data initiative seeks to provide crucial support to people affected by Amyotrophic Lateral Sclerosis and Multiple Sclerosis
Mamede de Carvalho, a renowned neurologist and the head of the Amyotrophic Lateral Sclerosis (ALS) Clinic at Centro Hospitalar Universitário Lisboa Norte (CHULN), situated at the p…
BLOG SECTIONTransforming Fracture Risk Assessment for Cancer Patients with Vertebral Metastases
Cutting-edge EU-funded project METASTRA unites an interdisciplinary team of experts to spearhead a transformative approach to revolutionize fracture risk assessment and personalize…
BLOG SECTIONUnleashing the IDPP@CLEF Potential: Assessing Predictive Algorithms and Enabling Data Sharing for Enhanced Research
Each year, the BRAINTEASER project organizes an open evaluation challenge, called iDPP@CLEF (Intelligent Disease Progression Prediction), to involve research groups from academia a…